Trial Profile
A Phase 2/3, Randomized, Observer-blind, Active-controlled, Multicenter Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 (Prototype) Booster Vaccine
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 03 Jan 2024
Price :
$35
*
At a glance
- Drugs Elasomeran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Moderna Therapeutics
- 06 Jul 2023 Status changed from active, no longer recruiting to completed.
- 03 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 03 Apr 2023 Planned End Date changed from 7 Apr 2023 to 23 Jun 2023.